On April 9, 2026 Oxford BioTherapeutics ("OBT"), is a clinical stage oncology company focused on the discovery and development of immuno-oncology (IO) and Antibody Drug Conjugate (ADC)-based therapies enabled by its OGAP-Verify platform reported a multi-year, selective target collaboration with Bristol Myers Squibb (NYSE: BMY, "BMS") focussed on the discovery and development of novel T-cell engager therapies for solid tumours.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
OBT will leverage its proprietary OGAP-Verify target discovery and validation platform, to identify novel, tumour-selective targets for solid cancers and generate next-generation T-cell engager molecules. The collaboration extends beyond discovery, with OBT assuming responsibility for the design and delivery of development candidates, highlighting the company’s expanding evolution into a fully integrated discovery and preclinical development platform. Subsequent research, development and commercialisation activities for these targets will be led by BMS.
Under the terms of the agreement, OBT will receive an upfront inclusive of research funding and the potential for significant downstream milestone payments and royalties on commercialised products from BMS. Financial terms were not disclosed.
The collaboration with BMS marks OBT’s third partnership with a major pharmaceutical company in the past 12 months, following strategic partnerships with GSK and Roche in 2025.
"Collaborating with Bristol Myers Squibb, a global leader in oncology, represents an important milestone for OBT and underscores the momentum behind our partnerships with leading pharmaceutical companies," said Christian Rohlff, PhD, Chief Executive Officer of OBT. "This new partnership builds on the proven strength of our platform to identify and validate highly differentiated, tumour-selective targets and reflects the growing confidence in our ability to translate that science into development-ready therapeutic candidates. By combining OGAP-Verify’s discovery and validation capabilities with Bristol Myers Squibb’s expertise in translating oncology innovation into clinical and commercial outcomes, we are confident that together we can advance a new generation of innovative cancer therapies that have the potential to make a meaningful difference for patients."
OBT’s OGAP-Verify discovery platform enables highly sensitive identification of oncology targets with improved attributes for drug development, supporting the creation of differentiated antibody-based therapies.
(Press release, Oxford BioTherapeutics, APR 9, 2026, View Source [SID1234664289])